Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.

Détails

ID Serval
serval:BIB_7C13D7931E14
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Périodique
Neurologist
Auteur(s)
Parfenov V., Du Pasquier R., Schluep M.
ISSN
2331-2637 (Electronic)
ISSN-L
1074-7931
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
19
Numéro
6
Pages
155-157
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
INTRODUCTION: Malignant variant is a rare subtype of multiple sclerosis (MS) that is rapidly progressive and may lead to significant disability or even death. No consensus exists on best management of this disorder, although corticosteroids and plasmapheresis are commonly used in the acute phase, followed either by MS-specific disease-modifying therapy or an immunosuppressant.
CASE REPORT: The patient is a 30-year-old man with relapsing-remitting MS previously well controlled with natalizumab, who has developed fulminant disease activity upon natalizumab cessation. In the acute phase, patient had a suboptimal response to multiple corticosteroid treatments but responded very well to plasmapheresis. Patient continued to have worsening disease activity despite fingolimod treatment. Disease control has been eventually achieved by switching to rituximab.
CONCLUSION: Rituximab treatment should be considered for a patient with fulminant MS who responded well to plasmapheresis.
Pubmed
Web of science
Création de la notice
02/02/2016 11:38
Dernière modification de la notice
03/03/2018 18:36
Données d'usage